Spravato (Esketamine) at Sonder: 5 Fast Facts

Spravato (esketamine) at Sonder is a safe, effective, and personalized treatment option for those whose depression has not responded to other approaches.

Spravato (esketamine) has garnered attention as a groundbreaking treatment for depression, particularly for those who have tried other treatment approaches with insufficient results.

Whether you’re considering it for yourself or just want to understand the latest in depression treatment options, we’re here to help you find the information you’re looking for.

Read on for 5 fast facts about Spravato (esketamine) at Sonder:

1. Spravato (esketamine) has a unique mechanism of action.

Spravato isn’t like your typical antidepressant. It functions as an NMDA receptor antagonist, which is quite different from the usual serotonin or norepinephrine-targeting antidepressants. By affecting glutamate, a neurotransmitter that plays a crucial role in mood regulation, Spravato offers a novel approach to alleviating symptoms of depression. This unique mechanism helps it stand out in the field of psychiatric treatments.

2. The FDA has approved Spravato (esketamine).

In March 2019, Spravato received FDA approval for treating adults with treatment-resistant depression (TRD). This means it is specifically designed for individuals who have not found relief from at least two other antidepressant medications. The FDA’s endorsement underscores its potential for helping those who have not responded to conventional treatments.

3. We administer it in a very specific way…

One of the distinctive features of Spravato is its delivery method. We administer is as a nasal spray, allowing for rapid absorption. Patients receive their doses in a clinical setting under the supervision of a healthcare provider. This method not only aids in the swift onset of effects but also ensures proper monitoring during treatment.

4. …and we monitor our patients closely.

As with any medication, Spravato comes with potential side effects, including dizziness, dissociation, nausea, and increased blood pressure. Due to these risks, we require patients to remain in our comfortable clinical setting for two hours post-administration so we can monitor them for any adverse reactions. This monitoring ensures that any issues are promptly addressed and helps maintain our high standard of patient safety.

5. Spravato (esketamine) at Sonder is a custom experience.

The treatment regimen for Spravato involves a structured schedule. Initially, we administer it twice a week for the first four weeks. After this phase, we may adjust the frequency based on individual response, with maintenance doses generally being administered weekly or biweekly. This flexible schedule helps in tailoring the treatment to each of our patient’s unique needs.

Want to learn more about Spravato (Esketamine) at Sonder?

Find answers to frequently asked questions right here.

Ready to experience Spravato (esketamine) at Sonder for yourself?

REQUEST AN APPOINTMENT NOW

Spravato (Esketamine) at Sonder